AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.
AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.
AstraZeneca has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely-watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.
AstraZeneca's sweeping new Cambridge, U.K., campus will be constructed with collaboration in mind, the company said, unveiling plans for the $500 million site it aims to open in 2016.
AstraZeneca is expanding iMed, its virtual R&D project, through a cardiovascular-focused agreement with Germany's Max Planck Institute of Molecular Physiology that will focus on early-stage research.
The pact focuses on identifying and selecting novel drug targets with the potential to become potent, selective therapeutics in the areas of oncology, inflammation and diabetes.
Plenty of AstraZeneca fans voiced their support for a standalone company when Pfizer tried to take the drugmaker over earlier this year. But actions speak louder than words, and now one vocal advocate is putting his money where his mouth is.
Pascal Soriot has raised the stakes on AstraZeneca's turnaround. The chief executive plunked down $3.4 million to buy more of his company's shares.
A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly good outcome for either company. The two pharmas aren't far apart on price, and any renewal of negotiations could come as early as August.
AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire--the latest totaling about $46.5 billion--it's not about to make Pfizer's same mistakes.